cenersen
Nucleic acidexperimental
Clinical trial activity
4 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2004 (NCT00074737)
Timeline
Indications
Mechanism of action
- Cellular tumor antigen p53AGONIST
TP53 agonist
- p53 mRNAANTISENSE INHIBITOR
p53 mRNA antisense inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2219776 ↗
- ChEMBLCHEMBL2108280 ↗
Also known as
- cenersen
- cenersen
- cenersen
- cenersen sodium
- cenersen sodium
- cenersen sodium
- el-625
- ol(1)p53
- ol(1)p53
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02243124 | Phase 1 | Sep 1, 2014 | Eleos, Inc., University of South Florida |
| NCT00967512 | Phase 2 | Jan 1, 2012 | Eleos, Inc. |
| NCT00636155 | Phase 2 | Feb 1, 2008 | Duke University, Eleos, Inc. |
| NCT00074737 | Phase 2 | Apr 1, 2004 | Eleos, Inc., State University of New York, Buffalo, University of California, San Diego, University of Chicago, University of Miami, University of Texas at Houston, Washington University in St. Louis |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eleos, Inc. | For profit | 4 | 3 | 2 | 2004 |
| Duke University | Academic/Hospital | 1 | 1 | 1 | 2008 |
| State University of New York, Buffalo | Academic/Hospital | 1 | 0 | 1 | 2004 |
| University of California, San Diego | Academic/Hospital | 1 | 0 | 1 | 2004 |
| University of Chicago | Academic/Hospital | 1 | 0 | 1 | 2004 |
| University of Miami | Academic/Hospital | 1 | 0 | 1 | 2004 |
| University of South Florida | Academic/Hospital | 1 | 0 | 1 | 2014 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2004 |
| Washington University in St. Louis | Academic/Hospital | 1 | 0 | 1 | 2004 |
9 organizations
Page 1 / 1